დასაწყისი · კატალოგი · პროფილი · ცხრილი
სუნთქვა BODY HANDBOOK
სუნთქვა · §12
Heated Tobacco (IQOS)
Heated tobacco devices like IQOS look like vapes but use real tobacco, heated at about a third of a cigarette's temperature — so most of the chemistry burning produces never gets made. For a current smoker who fully switches, that means dramatically less of the headline cigarette carcinogens going into the lungs and bloodstream. For everyone else, it's a nicotine product with no comparison to lean on. The trap is the marketing: the FDA authorised the "reduced exposure" claim and explicitly refused the "reduced risk" version — same data, different question — and no published trial has yet measured whether these devices actually help anyone quit smoking.
გადაწყვიტე · კურსი მტკიცებულება განვითარებადი თავი სუნთქვა

The exposure-reduction part is solid: a full-switching smoker drops the headline cigarette carcinogens by roughly 70 to 95 percent within weeks. The cessation part is the bit that's missing — the most recent Cochrane review couldn't find a single trial that measured whether anyone actually quit smoking using one of these, and every randomised trial in the evidence base was funded by the manufacturer. Three readers have three different answers: a smoker who has failed pharmacy aids and vaping has a real harm-reduction case to consider; a smoker who hasn't worked that ladder should walk it first; a never-smoker is being marketed a nicotine product against nothing on the other side.

A cigarette burns tobacco at about 900 °C and produces more than seven thousand chemicals, including dozens of known carcinogens, tar, and carbon monoxide. An IQOS holder heats a tobacco stick to roughly 320–350 °C with a small ceramic blade — a third of a cigarette's temperature, hot enough to release a nicotine aerosol, cool enough that most of the combustion chemistry doesn't get triggered. The headline numbers are real. Across the harmful-chemical panel the FDA tracks for cigarettes, full-switching smokers drop levels of carcinogens like NNK, benzene, and 1,3-butadiene by 70 to 95 percent within weeks, often approaching never-smoker levels on several of the most-studied markers (Lüdicke et al. 2018) (Mallock et al. 2018).

"Cool enough" is not "cool enough for zero chemistry," though. Independent chemical analyses describe what's happening inside the heat stick as incomplete combustion — a process called pyrolysis — and they find pyrolytic markers, polycyclic aromatic hydrocarbons, and a long tail of carbonyls in the aerosol that the marketing line "heat not burn" elides (Auer et al. 2017). A 2022 chemistry review catalogued eighty constituents that show up at higher levels in heated-tobacco aerosol than in cigarette smoke, including four possible or probable carcinogens (Uguna and Snape 2022). The honest summary isn't safe — it's dramatically less of the chemicals epidemiology has linked to cancer, plus a smaller panel of less-studied chemicals nobody can confidently grade yet.

One more pharmacology detail matters because it shapes the addiction risk: heated tobacco delivers nicotine to the blood faster and at a higher peak than a typical e-cigarette does, closer to a cigarette. That is what makes it a credible substitute for a current smoker — early vapes failed cessation trials partly by under-dosing the nicotine. It is also what makes it dependence-forming in a way that vapes used by never-smokers often aren't: the hit lands fast, in a few minutes, and the brain learns the cue at cigarette speed.

Does it actually help anyone quit?

This is the part the literature is straightforwardly thin on. The Cochrane Collaboration — the gold standard for medical evidence reviews — looked at thirteen studies covering about 2,700 smokers and found something striking: not a single trial reported whether anyone actually quit smoking using these devices. The trials measured exposure reduction and consumer acceptance, the things the manufacturers wanted to demonstrate. They did not measure cessation. And every randomised trial in the evidence base was funded by the manufacturer themselves (Tattan-Birch et al. 2022).

What the published trials do show is the biomarker story: in randomised studies of Japanese smokers asked to switch fully for up to ninety days, urinary NNAL — the dominant biomarker for the lung carcinogen NNK — carboxyhaemoglobin, and biomarkers of benzene, butadiene, and acrolein exposure all dropped roughly 70 to 95 percent compared with continued smoking (Lüdicke et al. 2018). An independent reanalysis of the manufacturer's own data confirmed those exposure drops are real — and added an uncomfortable second finding: on twenty-three of twenty-four biomarkers of biological harm (inflammation, oxidative stress, endothelial function, lung function), the same trials showed no significant difference between IQOS users and continued smokers at six months (St Helen et al. 2018). The exposure dropped. The harm signals, at the time horizon and sample size measured, did not. That gap is the centre of the controversy.

Whether that gap reflects a power problem (six months is short, the trials weren't large), or that nicotine plus the residual aerosol drives a substantial share of cigarette-attributable disease independently, or that the long-term picture will look different — nobody knows yet, because nobody has lived on one of these devices for thirty years. Heated tobacco first hit the Japanese market in 2014. The cancer and cardiovascular-incidence answer for someone who switches in their thirties and stops in their sixties is a question the data physically can't answer for at least another decade.

The population-level signal that does exist is Japan. Heated tobacco's share of total Japanese tobacco sales went from 3 percent in 2016 to 23.5% in 2019; cigarette sales had been declining at about 3 percent a year before IQOS launched, then accelerated to a 16 percent annual decline through 2019 (Cummings et al. 2020). The staggered regional rollout makes a credible natural experiment: cigarette sales began dropping in each Japanese region when IQOS launched there locally, not all at once (Stoklosa et al. 2020). The catch sitting inside that result is that most Japanese heated-tobacco users are also still smoking cigarettes — dual use, not substitution, is the modal lived pattern.

Three readers, three answers

Different starting points produce opposite expected-value calculations on the same device.

If you currently smoke and have failed everything else. The argument here is the same harm-reduction argument that put vaping in U.K. cessation guidelines, weaker. Full substitution — no cigarettes, just the device — measurably reduces your exposure to the chemicals that drive lung cancer, COPD, and a meaningful share of cardiovascular disease (Lüdicke et al. 2018). If you've tried varenicline, tried nicotine-replacement therapy, tried vaping, and you're still on cigarettes, this is the next rung. It is not a guarantee — the disease-endpoint answer doesn't yet exist — but the continued-smoking counterfactual is known severe harm with a measured timeline. Refusing a measured exposure reduction in service of an abstinence-only orthodoxy costs life-years.

If you currently smoke and haven't worked the ladder yet. Don't start here. The cessation evidence for prescription medication (varenicline, bupropion) and for combination nicotine-replacement therapy is solid; the cessation evidence for vaping reached the gold standard in 2024; the cessation evidence for heated tobacco is essentially absent (Tattan-Birch et al. 2022). Walk down the evidence-graded ladder before you reach for the product nobody has measured for the thing you actually want.

If you've never smoked. None of the harm-reduction case is on the table for you. Whatever the long-term cost of using one of these turns out to be — modest, large, somewhere in between — you'd be buying it against nothing. The "reduced exposure" framing is a comparison to a baseline you don't have. And because the nicotine delivery profile is close to a cigarette's, the dependence you'd form would be cigarette-class, not vape-class — fast cue learning, hard exit. The honest answer is the boring one: don't start.

What the marketing softens

"It's smoke-free." The visible cues — no flame, no ash, no glowing ember — make this feel obviously true to a user. The chemistry is less generous. Independent analyses describe what's happening as incomplete combustion of solid tobacco, and they find pyrolytic markers, polycyclic aromatic hydrocarbons, and carbon-rich particulates in the aerosol — the chemical fingerprint of smoke, with most (not all) of the worst stuff turned down (Auer et al. 2017). The "smoke-free" framing has been load-bearing in regulatory arguments for indoor-use exemptions in some places; it is not load-bearing on the chemistry itself.

"The FDA approved it as safer than cigarettes." The FDA did something specific and narrow in 2020: it authorised the manufacturer to make a marketing claim about reduced exposure to specific harmful chemicals, on the basis of the biomarker data. It explicitly did not authorise any claim about reduced risk of disease, and the announcement spelled out: "the FDA's decision today does not mean these products are safe or 'FDA approved'" (FDA 2020). Exposure-reduced is a chemistry claim. Risk-reduced is a disease claim. The agency authorised the first and refused the second. Consumer coverage routinely conflates them; the World Health Organization, looking at the same underlying data, recommends regulating heated tobacco as a conventional tobacco product, with no harm-reduction endorsement at all (WHO 2023).

"It's basically a vape." Different chemistry, different product. A vape heats a propylene-glycol-and-glycerin liquid with no tobacco in it. A heated-tobacco device heats real tobacco and generates an aerosol that sits chemically in the cigarette family — most of the worst constituents turned down, the substrate still tobacco. The cessation evidence base is also asymmetric: vaping is the most strongly evidenced quit aid in modern tobacco research; heated tobacco has essentially none (Tattan-Birch et al. 2022). The marketing positioning is similar; the things they actually do are not the same.

"It doesn't smell." It smells less than cigarettes — no ash, no third-hand residue on fingers and clothes — and frequent users acclimate to the residual odour quickly. People around them don't, particularly indoors. "Much less smell" is true; "no smell" is overclaim.

If you're a smoker considering one

There is no validated quit-with-it protocol because no trial has measured one. The pattern that carries the biomarker-validated evidence — and only the biomarker-validated evidence, not the disease-endpoint evidence — is straightforward.

Where this goes wrong

Three patterns swallow most attempts.

Dual use. You buy the device. You keep smoking — maybe fewer cigarettes, maybe the same number on social occasions and the device indoors. This is the modal pattern in Japan, the largest market, where most heated-tobacco users still smoke cigarettes too (Cummings et al. 2020). The biomarker reductions vanish at even modest concurrent cigarette use. Dual use captures none of the harm-reduction case the product's evidence base actually rests on.

Indefinite continuation. The full switcher who never relapses to cigarettes, never comes off the device. By design this is the harm-reduction outcome, but it is a multi-decade nicotine dependence on an aerosol that did not exist a decade ago. The long-tail safety profile is not knowable yet, and a meaningful share of people who get on these devices appear unlikely to ever come off.

Symbolic substitution. The smoker who buys the device as a hedge — a way to feel as if quitting is in progress without actually doing the thing that quits cigarettes. Treated as a regulatory or social arbitrage (indoor use permitted in more places, fewer comments from coworkers), the device is functioning as cover, not as cessation. The biomarker math is unforgiving about this; the felt sense of progress is not the same as progress.

What changes if you fully switch from cigarettes

The first week, the smell on your clothes and breath stops. Taste and smell partially come back; coffee gets stronger; food gets stronger. Your partner stops mentioning the ashtray. The visible cues — outdoor smoking breaks in the rain, ash on the car seat, the lighter you always need to find — are gone.

By a month or two, the morning cough fades. The flight of stairs to your flat is easier than it had quietly become. Urinary biomarkers for the main lung-cancer-relevant carcinogen drop roughly 70 to 95 percent compared with continued smoking, approaching never-smoker levels for several markers by week 8 to 12 (Lüdicke et al. 2018). Carbon monoxide in your blood drops back to baseline within days, exactly as it would if you had quit cleanly.

By a year, exercise tolerance has rebuilt — partially. People close to you don't see the smoker's face setting in the way it would have. The chronic cardiovascular impacts of continued combustion have been removed from the trajectory, though the device itself still produces measurable acute heart-rate and endothelial effects after each session (Biondi-Zoccai et al. 2019).

By a decade — the part nobody has measured directly — your individual story is one of three. The optimistic version is closer to a full cigarette quitter than to a continued smoker, because the carcinogen exposure was much closer to a quitter's. The pessimistic version is closer to half-way, because of the chronic nicotine and the residual aerosol toxicants nobody fully characterised. Nobody on the planet has been on a heated-tobacco device for thirty years yet; that answer is at least a decade or two off. The asterisk that does not disappear: you are still using nicotine. Most people who switch keep using it for years.

Adjacent territory this entry doesn't cover. Cigarette smoking itself — the substance this is being substituted for, with its own much larger evidence base on disease and cessation. Nicotine vaping, the cessation tool with by far the strongest published evidence and the right next step for most smokers who have failed nicotine-replacement therapy. Prescription cessation medication (varenicline, bupropion) — both with stronger one-year quit outcomes than any inhaled-substitute approach. Nicotine-replacement therapy itself — the patches, gum, lozenges your pharmacy stocks. Smokeless tobacco such as snus, a separate category with its own oral-cancer and cardiovascular profile. And the country-by-country regulatory patchwork — FDA review, the EU's Tobacco Products Directive, Japan's tobacco-product framework, Australia's restrictions — which is the under-discussed reason local availability looks the way it does.

·
12